![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-announces-pricing-of-4-0-million-registered-direct-offering-302184547.html
https://www.contractpharma.com/contents/view_breaking-news/2024-06-20/brainstorm-cell-therapeutics-names-new-evp-coo/9769
https://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-to-present-new-biomarker-data-suggesting-als-patients-may-benefit-from-longer-term-treatment-with-nurown-302149897.html
https://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-announces-peer-reviewed-publication-of-biomarker-data-from-nurowns-phase-3-clinical-trial-in-als-302112956.html
https://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-to-unveil-phase-3b-nurown-trial-design-at-mda-clinical-and-scientific-conference-302072354.html
https://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-submits-special-protocol-assessment-spa-request-to-fda-for-phase-3b-trial-of-nurown-in-als-302069799.html
https://www.prnewswire.com/news-releases/brainstorm-granted-patents-for-allogeneic-exosome-platform-product-in-neurological-disorder-treatments-302022322.html
https://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-announces-outcome-of-fda-meeting-on-nurown-in-als-302008950.html
https://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-announces-in-person-meeting-with-the-fda-to-discuss-confirmatory-phase-3-trial-for-nurown-in-als-301993513.html
https://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-to-present-at-6th-annual-als-research-symposia-301992034.html